

## ORIGINAL ARTICLE

# PREVALENCE OF MORTALITY AND ITS DISTRIBUTION BY SEX AND AGE GROUPS IN INDOOR COVID-19 PATIENTS IN D.I.KHAN DIVISION, PAKISTAN

 Muhammad Aamir<sup>1</sup>,  Waleed Ahmad<sup>1</sup>,  Bashir Ahmad<sup>1</sup>,  Abdurrehman Khan<sup>1</sup>,  
 Muhammad Fawad<sup>1</sup>,  Muhammad Abdullah<sup>2</sup>

<sup>1</sup>Department of Medicine, Gomal Medical College, D.I.Khan, <sup>2</sup>Department of Ophthalmology, King Edward Medical University, Lahore, Pakistan

## ABSTRACT

**Background:** COVID-19 has become one of the leading causes of morbidity and mortality. The objectives of this study were to determine the prevalence of mortality and its distribution by sex and age groups in indoor COVID-19 patients in D.I.Khan Division, Pakistan.

**Materials & Methods:** This cross-sectional study was conducted in the Department of Medicine, Gomal Medical College, D.I.Khan, Pakistan. A sample of 438 patients with positive SARS-CoV-2 RT-PCR was selected. Sex & age-groups were two demographic and presence of mortality was a research variable. The data type for all variables was nominal, except ordinal age groups. Prevalence & distribution were described by count and percentage with 95%CI. The hypotheses were tested by chi-square goodness of fit test.

**Results:** Out of 438 COVID-19 patients, mortality was 43 (9.82%), including 34 (7.76%) men and nine (2.06%) women. The mortality was 0% for 0-19 years, four (0.92%) for 20-39 years, 12 (2.74%) for 40-59 years and 27 (6.16%)  $\geq 60$  years. Our mortality 9.82% was lower than expected 20.95% ( $p < .001$ ). It was higher in men than women ( $p < .001$ ). It was highest in age group  $\geq 60$  years, while 0% in 0-19 years. It was similar to expected by sex ( $p = .070$ ) and age group ( $p < .207$ ).

**Conclusion:** Our study showed 9.82% mortality in indoor COVID-19 patients. The mortality was lower than expected. The mortality was higher in men than women. It was highest in elderly, while zero in children and adolescents. It was similar to expected by sex and age group.

**KEYWORDS:** COVID-19, Pneumonia, Prevalence, Distribution, Children, Elderly, Females, Males, Pandemic, D.I.Khan, Division, Chi-square Goodness of fit Test.

**Cite as:** Aamir M, Ahmad W, Ahmad B, Khan A, Fawad M, Abdullah M. Prevalence of mortality and its distribution by sex and age groups in indoor COVID-19 patients in D.I.Khan Division, Pakistan. Gomal J Med Sci 2021 Jul-Sep; 19(3):91-7. <https://doi.org/10.46903/gjms/19.03.1029>

## 1. INTRODUCTION

**1.1 Background:** Coronavirus disease 19 (COVID-19) is an infectious disease caused by a novel coronavirus, which has been named by International Committee on Taxonomy of Viruses (ICTV) as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).<sup>1</sup>

### Corresponding Author:

Dr. Muhammad Aamir  
Department of Medicine  
Gomal Medical College  
D.I.Khan, Pakistan  
E-mail: [aamirgandapur998@gmail.com](mailto:aamirgandapur998@gmail.com)

**Date Submitted:** 11-04-2021

**Date Revised:** 20-06-2021

**Date Accepted:** 26-06-2021

Corona viruses belong to subfamily Coronavirinae in the Coronaviridae family, which belongs to Nidovirales order.<sup>2</sup> Corona virus is single stranded RNA virus & the subfamily Coronavirinae is genotypically divided into four genera: alpha, beta, gamma & delta Coronaviruses.<sup>3</sup> The first case of COVID-19 was reported in December 2019 in Wuhan, China. The World Health Organization (WHO) announced COVID-19 as a global pandemic on March 11, 2020. The COVID-19 first patient in Pakistan was reported on February 26, 2020 in Karachi.<sup>4</sup>

Patients having COVID-19 may present with symptoms of fever, cough, myalgia & on investigations have normal or decreased leukocytes count & radiographic evidence of pneumonia.<sup>5</sup> In the past 2 decades, corona virus has caused three epidemic

outbreaks, namely severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) & COVID-19.<sup>6</sup> In SARS-CoV-2, the severity of disease ranges from common cold and pneumonia to severe acute respiratory distress syndrome which can lead to death.<sup>7</sup> Recent epidemiological data indicate that there may be a gender predisposition to COVID-19, with men predisposed to being most severely affected, and older men accounting for most deaths.<sup>8</sup> Majority of deaths in COVID-19 were due to complications related to sepsis, ARDS & multi organ failure in adults with co-morbidities, whereas children having COVID-19 had better prognosis as compared to adults.<sup>9</sup>

Undurraga, et al.<sup>10</sup> reported 444,921 cases of COVID-19 from Chile, Latin America, from March 3, 2020 to August 31, 2020, studied by Ministry of Health Surveillance EPIVIGILA. Overall mortality was 15,756 (3.54%) ( $15,756 \times 100 / 444,921 = 3.54$ ). This mortality included 9,035 (2.03%) ( $9,035 \times 100 / 444,921 = 2.03$ ) men and 6,721 (1.51%) ( $6,721 \times 100 / 444,921 = 1.51$ ) women. Mortality by various age groups was as following; 33 (0.01%) ( $33 \times 100 / 444,921 = 0.01$ ) in 0-9 years, 20 (0.0044%) ( $20 \times 100 / 444,921 = 0.0044$ ) in 10-19 years, 97 (0.02%) ( $97 \times 100 / 444,921 = 0.22$ ) in 20-29 years, 249 (0.06%) ( $249 \times 100 / 444,921 = 0.06$ ) in 30-39 years, 556 (0.12%) ( $556 \times 100 / 444,921 = 0.12$ ) in 40-49 years, 1581 (0.36%) ( $1581 \times 100 / 444,921 = 0.36$ ) in 50-59 years, 3205 (0.72%) ( $3205 \times 100 / 444,921 = 0.72$ ) in 60-69 years, 4395 (0.98%) ( $4395 \times 100 / 444,921 = 0.98$ ) in 70-79 years and 5620 (1.26%) ( $5620 \times 100 / 444,921 = 1.26$ ) in  $\geq 80$  years age group.

Munayco, et al.<sup>11</sup> reported a study from Peru for the period of March to May 2020, with overall mortality by COVID-19 as 7,660 (5.92%) out of 129,148 suspected COVID-19 patients. Distribution by sex was more for men 5,508 (4.26%) ( $5508 \times 100 / 129148 = 4.26$ ) than women 2,152 (1.66%) ( $2152 \times 100 / 129148 = 1.66$ ). The distribution by age groups was 21 (0.02%) ( $21 \times 100 / 129148 = 0.02$ ) for 0-9 years, 14 (0.01%) ( $14 \times 100 / 129148 = 0.01$ ) for 10-19 years, 51 (0.04%) ( $51 \times 100 / 129148 = 0.04$ ) for 20-29 years, 218 (0.17%) ( $218 \times 100 / 129148 = 0.17$ ) for 30-39 years, 639 (0.49%) ( $639 \times 100 / 129148 = 0.49$ ) for 40-49 years, 1430 (1.11%) ( $1430 \times 100 / 129148 = 1.11$ ) for 50-59 years, 2264 (1.75%) ( $2264 \times 100 / 129148 = 1.75$ ) for 60-69 years, 1837 (1.42%) ( $1837 \times 100 / 129148 = 1.42$ ) in 70-79 years and 1186 (0.92%) ( $1186 \times 100 / 129148 = 0.92$ ) in  $\geq 80$  years age group.

Wu C, et al.<sup>12</sup> from Wuhan, China from December 25, 2019 to February 13, 2020 reported 201 COVID-19 patients. Overall mortality was 44 (21.89%) ( $44 \times 100 / 201 = 21.89$ ). This mortality included 29 (14.43%) ( $29 \times 100 / 201 = 14.43$ ) men and 15 (7.46%) ( $15 \times 100 / 210 = 7.46$ ) women.

Sarfraz, et al.<sup>13</sup> reported 170 serious indoor COVID-19 positive cases from Karachi, Pakistan from March 19 to June 7, 2020. Overall mortality

was 67 (39.41%) ( $67 \times 100 / 170 = 39.41$ ). This mortality included 52 (30.59%) ( $52 \times 100 / 3851 = 30.59$ ) men and 15 (8.82%) ( $15 \times 100 / 175 = 8.82$ ) women. Age group wise mortality was 24 (14.12%) ( $24 \times 100 / 170 = 14.12$ ) in  $\leq 60$  years and 43 (25.29%) ( $43 \times 100 / 170 = 25.29$ ) in  $> 60$  years.

**1.2 Research Objectives (ROs):** The objectives of this study were;

**RO 1:** To determine the prevalence of mortality of COVID-19 in D.I.Khan Division.

**RO 2-3:** To determine the distribution of COVID-19 mortality by sex & age groups in D.I.Khan Division.

**1.3 Research (Null) Hypotheses (RHs)**

**H<sub>01</sub>:** The observed prevalence of mortality of COVID-19 is similar to its expected prevalence in D.I.Khan Division.

**H<sub>02</sub>:** The observed distribution of mortality of COVID-19 by sex is similar to its expected distribution in D.I.Khan Division, Pakistan.

**H<sub>03</sub>:** The observed distribution of mortality of COVID-19 by sex is similar to its expected distribution in D.I.Khan Division.

**1.4 Significance:** Having local data available on prevalence & distribution of mortality in COVID-19 cases in D.I.Khan Division, we can know about the sex & age groups having severe disease and highest mortality. This data can help public health officials to pursue potent actions to decrease mortality, particularly in age groups with highest risk of mortality.

## 2. MATERIALS AND METHODS

**2.1 Study Design, Setting & Duration:** This cross-sectional study was conducted in the Department of Medicine, Gomal Medical College, D.I.Khan, Pakistan from March 14, 2020 to April 6, 2021. The data was collected from IPMS system of COVID-19 ICU, HDU & Isolation Unit of MMM Teaching Hospital, D.I.Khan. Approval for the project was granted by the Institutional Ethical Committee.

**2.2 Population & Sampling:** As per 2017 census, the population of D.I.Khan Division was 2,803,147. For 2020, it was assumed to be 3 million; our population at risk. Using Raosoft<sup>®</sup> online sample size calculator,<sup>14</sup> sample size was calculated to be 438, with 95%CL, 0.932% margin of error, assumed prevalence of COVID-19 as 1% and population size of 3 million. The technique was consecutive. All the indoor (ICU, HDU & Isolation Unit) COVID-19 patients were eligible for inclusion in the study. A total of 2,825 suspected COVID-19 patients were admitted in ICU, HDU and Isolation Unit for the period of the study; out of which 438 cases were confirmed by SARS-CoV-2 RT-PCR.

**2.3 Conduct of Procedure:** The first step was sample collection which was conducted by nasopharyngeal swab. The swab was put in a vial containing

buffer solution which preserves the virus till the time the sample is processed. The second step was RNA extraction process, which converts RNA to DNA using Mag-Bind RNA Extraction Kit (Maccura & Big Fish companies). The third step was Master Mix process conducted in OOVSIGN machine. The final step is Amplification by PCR machine (Singuway Company) with SARS-CoV-2 specific primers. The presence of viral RNA indicates active SARS-CoV-2 infection. All these patients were investigated and managed as per standard clinical protocols.

**2.4: Data Collection Plan:** Sex (men/ women) & age-groups (0-19 years i.e. children & adolescents, 20-39 years i.e. early adult hood, 40-59 years i.e. late adult hood and ≥60 years i.e. elderly) were our two demographic variables and the presence of mortality was our single research variable. The data type for all these variables was nominal except age groups which was ordinal. A structured Performa was used as data collection tool to collect primary data from patients. Secondary data was collected through literature research.

**2.5 Data Analysis Plan**

**2.5.1 Descriptive Statistics and Estimation of Parameters:** All three variables being categorical were described by count & percentage. The estimated population parameters were given as confidence interval (CI) for proportion at 95% confidence level

using Wilson score interval for binominal distribution. This calculation was done by using Statistics Kingdom calculator.<sup>15</sup>

**2.5.2 Hypotheses Testing:** Three hypotheses were substantiated by chi-square goodness of fit test,<sup>16,17</sup> using online statistical calculators; Statulator<sup>18</sup> for  $H_{01}$  &  $H_{02}$  and Statistics Kingdom Calculator<sup>15</sup> for  $H_{03}$ . Observed & expected counts, chi-square values are given with significance (p-value).

**3. RESULTS**

**3.1.1 Prevalence of mortality:** The overall mortality was 9.82% (95%CL 07.37-12.96) i.e. 43 among 438 COVID-19 patients. (Table 3.1.1)

**3.1.2: Distribution of mortality by sex & age groups:** Prevalence of mortality was higher in men 7.76% (95%CL 5.60-10.65) than women 2.06% (95%CL 1.08-3.85). It was highest in age group ≥60 years 6.16% (95%CL 4.27-8.82), followed by 40-59 years 2.74% (95%CL 1.57-4.72). (Table 3.1.2)

**3.2 Hypotheses Testing**

**3.2.1 Observed vs. expected prevalence of mortality ( $H_{01}$ ):** Chi-square goodness-of-fit test verifies the difference between the observed counts from our sample (n=438) in column 2 (C2) against expected counts (C3) from a study by Wu C, et al.<sup>12</sup> from Wuhan, China (n=210). With difference in sample sizes, the expected counts are adjusted to

**Table 3.1.1: Prevalence of mortality in indoor COVID-19 patients in D.I.Khan Division**

Variable	Attributes	Sample Statistics		95%CI for proportion	
		Count	Percentage	Lower	Upper
Presence of mortality	Yes	43	09.82	07.37	12.96
	No	395	90.18	87.03	92.62
Total		438	100%	Population Parameters	

**Table 3.1.2: Distribution of mortality by sex & age groups in indoor COVID-19 patients in D.I.Khan Division, Pakistan (n=438)**

Variables	Attributes	Sample Size	Sample Statistics		95%CI for proportion	
			Count	Percentage	Lower	Upper
Sex	Men	318	34	$34*100/438=7.76$	05.60	10.65
	Women	120	09	$09*100/438=2.06$	01.08	03.85
Age Groups (Years)	0-19	27	0	0	0	0
	20-39	162	04	$4*100/438=0.92$	00.35	02.32
	40-59	157	12	$12*100/438=2.74$	01.57	04.72
	≥60	92	27	$27*100/438=6.16$	04.27	08.82
Mortality	Yes	438	43	$43*100/438=9.82$	07.37	12.96
	No		395	$395*100/438=90.18$	87.03	92.62
Total			438	100%	Population parameters	

our sample size (C4). C5, C6 & C7 shows relevant percentages. (Table 3.2.1.1)

With p-value <.001, H<sub>01</sub> is rejected, confirming that the observed counts are different from the expected counts. Simply, our observed prevalence 9.82% is lower than expected prevalence 20.95% from a study by Wu C, et al.<sup>12</sup> (Table 3.2.1.2)

**3.2.2 Observed vs. expected distribution of COVID-19 mortality by sex (H<sub>02</sub>):** Chi-square goodness-of-fit test testifies the difference between the observed counts from our sample (n=43) in column 2 (C2) against expected counts (C3) from a

study by Wu C, et al.<sup>12</sup> from Wuhan, China (n=210). With difference in sample sizes/ denominators, the expected counts are adjusted to our sample size (C4). C5, C6 & C7 shows relevant percentages. (Table 3.2.2.1)

With p-value .070, H<sub>02</sub> is accepted, confirming that the observed counts are statistically similar to the expected counts. Simply, our observed prevalence 7.76% for men is similar to what was expected 6.47% for men and our observed prevalence 2.06% for women is similar to what was expected 3.35% for women from a study by Wu C, et al.<sup>12</sup> (Table 3.2.2.2)

**Table 3.2.1.1: Observed, expected & adjusted expected counts and %ages for prevalence of mortality in indoor COVID-19 patients in D.I.Khan Division, Pakistan (n=438)**

Column 1- Mortality	C2-Observed counts	C3-Expected counts	C4-Adjusted expected counts	C5-Observed %ages	C6-Expected %ages	C7-Adjusted expected %
Yes	43	44	44*438/210 =91.77	9.82%	20.95%	91.77*100/438 =20.95%
No	395	166	166*438/210 =346.23	90.18%	79.05%	346.23*100/438 =79.05%
Total	438	210	438	100%	100%	100%

**Table 3.2.1.2: Observed vs. expected prevalence of mortality in indoor COVID-19 patients in population of D.I.Khan Division, Pakistan (n=438)**

Presence of Mortality	Observed count (proportion)	95%CI for proportion		Expected count (proportion)	Chi-square test		Z test	
		Lower	Upper		Σχ <sup>2</sup>	p-value	Z-value	p-value
Yes	43 (0.10)	0.07	0.13	91.77 (0.21)	32.78	<.001	-5.73	<.001
No	395 (0.90)	0.87	0.93	346.23 (0.79)			5.73	<.001
Total	438 (1.00)			438 (1.00)	H <sub>01</sub> rejected at alpha .05		d.f.=1	

**Table 3.2.2.1: Observed, expected & adjusted expected counts and %ages for distribution of mortality by sex in indoor COVID-19 patients in D.I.Khan Division, Pakistan (n=438)**

Column1- Sex	C2-Observed counts	C3-Expected counts	C4-Adjusted expected counts	C5-Observed %ages	C6-Expected %ages	C7-Adjusted expected %
Men	34	29	29*43/44 =28.34	34*100/438 =7.76%	29*100/210 =13.81%	28.34*100/438 =6.47%
Women	09	15	15*43/44 =14.66	9*100/438 =2.06%	15*100/210 =7.14%	14.66*100/438 =3.35%
Total	43	44	43	43*100/438 =9.82%	44*100/210 =20.95%	43*100/438 =9.82%

**Table 3.2.2.2: Observed vs. expected distribution of mortality by sex in indoor COVID-19 patients in D.I.Khan Division, Pakistan (n=438)**

Mortality by sex	Observed count (proportion)	95%CI for proportion		Expected count (proportion)	Chi-square test		
		Lower	Upper		Σχ <sup>2</sup>	d.f.	p-value
Men	34 (0.79)	0.67	0.91	28.34 (0.66)	3.27	1	.070
Women	09 (0.21)	0.09	0.33	14.66 (0.34)			
Total	43 (1.00)			43 (1.00)	H <sub>01</sub> accepted at alpha .05		

**Table 3.2.3.1: Observed, expected & adjusted expected counts and %ages for distribution of mortality by age groups in indoor COVID-19 patients in D.I.Khan Division (n=438)**

Column 1-Age groups	C2-Observed counts	C3-Expected counts	C4-Adjusted expected counts	C5-Observed %ages	C6-Expected %ages	C7-Adjusted expected %ages
0-19 years	0	35	$35 \times 43 / 7660 = 0.196$	$0 \times 100 / 438 = 0\%$	$35 \times 100 / 129148 = 0.03\%$	$0.196 \times 100 / 438 = 0.05\%$
20-39 years	04	269	$269 \times 43 / 7660 = 1.510$	$4 \times 100 / 438 = 0.92\%$	$269 \times 100 / 129148 = 0.21\%$	$1.510 \times 100 / 438 = 0.34\%$
40-59 years	12	2069	$2069 \times 43 / 7660 = 11.615$	$12 \times 100 / 438 = 2.74\%$	$2069 \times 100 / 129148 = 1.60\%$	$11.615 \times 100 / 438 = 2.65\%$
≥60 years	27	5287	$5287 \times 43 / 7660 = 29.679$	$27 \times 100 / 438 = 6.16\%$	$5287 \times 100 / 129148 = 4.09\%$	$29.679 \times 100 / 438 = 6.78\%$
Total	43	7660	43	9.82%	$7660 \times 100 / 129148 = 5.93\%$	$43 \times 100 / 438 = 9.82\%$

**Table 3.2.3.2: Observed vs. expected distribution of mortality by age groups in indoor COVID-19 patients in D.I.Khan Division, Pakistan (n=438)**

Age Groups	Observed Counts (O)	Expected Counts(E)	O-E	(O-E) <sup>2</sup>	χ <sup>2</sup>	Σχ <sup>2</sup>	p-value
00-19 years	00	00.20	-0.20	0.04	0.20	4.56	.207
20-39 years	04	01.51	2.49	6.20	4.11		
40-59 years	12	11.61	0.39	0.15	0.01		
≥ 60 years	27	29.68	-2.68	7.18	0.24		
Total	43	43	00	H <sub>03</sub> accepted at alpha .05			d.f.=3

**3.2.3 Observed vs. expected distribution of COVID-19 mortality by age groups (H<sub>02</sub>):** Chi-square goodness-of-fit test testifies the difference between the observed counts from our sample (n=438) in column 2 (C2) against expected counts (C3) from a study by Munayco, et al.<sup>11</sup> from Peru (n=129,148). With difference in sample sizes/ denominators, the expected counts are adjusted to our sample size (C4). C5, C6 & C7 shows relevant percentages. (Table 3.2.3.1)

With p-value 0.207, H<sub>02</sub> was accepted, confirming that the observed counts are statistically similar to the expected counts. Simply, our observed prevalence in each of our four age groups is similar to what was expected for these four age groups from a study by Munayco, et al.<sup>11</sup> from Peru (n=129,148). (Table 3.2.3.2)

#### 4. DISCUSSION

**4.1 Prevalence of mortality in indoor COVID-19 patients (H<sub>01</sub>):** The prevalence of mortality in COVID-19 in our study was 9.82% (95% CI 7.37%-12.96%). Higher mortality to our study was reported by Sarfaraz, et al.<sup>13</sup> from Karachi, Pakistan from March 19 to June 7, 2020 as 39.411764% and by Wu C, et al.<sup>12</sup> from Wuhan, China for the period from December 25, 2019 to February 13, 2020 as 21.89%.

Lower prevalence was reported by Undurraga, et al.<sup>10</sup> from Chile, Latin America from March 3 to August 31, 2020 as 3.5413% and Munayco, et al.<sup>11</sup> from Peru for the period of March to May, 2020 as 5.92%. No Study could be retrieved from the literature which showed similar prevalence of COVID-19 mortality to our study.

**4.2 Distribution of mortality in indoor COVID-19 patients by sex (H<sub>02</sub>):** The prevalence of COVID-19 mortality in our study was more in men 7.76% (95% CI 5.60-10.65) than women 2.06% (95% CI 1.08-3.85). Similar to our study was reported by Undurraga, et al.<sup>10</sup> from Chile, Latin America with higher mortality 2.0306% in men than 1.5106% women and by Munayco, et al.<sup>11</sup> from Peru, North America having higher mortality 4.26% in men than 1.66% women. Similarly Wu C, et al.<sup>12</sup> from Wuhan, China reported higher mortality 14.43% in men than 7.46% women and Sarfaraz, et al.<sup>13</sup> from Karachi, Pakistan reported higher mortality 30.59% in men than 8.82% women.

No study could be retrieved from literature which showed similar or higher mortality in women than men.

**4.3 Distribution of COVID-19 mortality in indoor patients by age groups (H<sub>03</sub>):** The prevalence of COVID-19 mortality in our study was highest 6.1644% (4.27-8.82) in age group ≥60 years & lowest 0% in 0-19 years age group. Similar to our study was

reported from Peru by Munayco, et al.<sup>11</sup> from March to May 2020 having highest 4.0937% mortality in  $\geq 60$  years age group and lowest 0.0271% in 0-19 years. Matching to our study was also reported from Chile, North America by Undurraga, et al.<sup>10</sup> having highest mortality 0.01191% in  $\geq 60$  years age group & lowest 2.2509% in 0-19 years. None of the study from literature was having mortality higher in reciprocal order.

This study has few limitations. Firstly, some of the patients could not be followed up to their final outcome, since some patients were discharged once their symptoms were improved. Secondly few patients were also referred on their own request to higher centers for the management.

This study provides an important data on COVID-19 mortality distribution on basis of sex & various age groups. So, timely identification of COVID-19 patients at high risk of mortality can significantly improve proper management and resource allocation within hospitals. This study helps in providing data-driven approach to the understanding of male-female mortality risk and age related mortality risk. Without these data, the public are unaware about their disease risk and public policy responses cannot be specifically targeted.

**4.4 Marwat Logical Trajectory of Research Process:** We have adapted this logical and chronological trajectory in this study as devised by Dr. Muhammad Marwat.<sup>19-22</sup>

## 5. CONCLUSIONS & RECOMMENDATIONS

Our study showed 9.82% mortality in indoor COVID-19 patients. The mortality was lower than expected. The mortality was higher in men than women. It was highest in elderly, while zero in children and adolescents. It was similar to expected by sex and age group.

## REFERENCES

- World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report- 65. Geneva: World Health Organization; 2020.
- Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A. COVID-19: Virology, biology and novel laboratory diagnosis. *The J Gene Med* 2021 Feb;23(2):e3303. <https://doi.org/10.1002/jgm.3303>
- Hosseini ES, Kashani NR, Nikzad H, Azadbakht J, Bafrani HH, Kashani HH. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. *Virology* 2020 Dec 1;551:1-9. <https://doi.org/10.1016/j.virol.2020.08.011>
- Abid K, Bari YA, Younas M, Tahir Javaid S, Imran A. Progress of COVID-19 epidemic in Pakistan. *Asia Pac J Public Health* 2020 May;32(4):154-6. <https://doi.org/10.1177/1010539520927259>
- Wit E de, Doremalen NV, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging corona virus. *Nat Rev Microbiol* 2016;14: 523-534. <https://doi.org/10.1038/nrmicro.2016.81>
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new corona virus of probable bat origin. *Nature* 2020;579(7798):270-3. <https://doi.org/10.1038/s41586-020-2012-7>
- Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. *J Virol* 2007;81(16):8692-706. <https://doi.org/10.1128/JVI.00527-07>
- Papadopoulos V, Li L, Samplaski M. Why does COVID-19 kill more elderly men than women? Is there a role for testosterone? *Andrology* 2021 Jan;9(1):65-72. <https://doi.org/10.1111/andr.12868>
- Chan KS, Zheng JP, Mok YW, Li YM. SARS: prognosis, outcome and sequel. *Respirology* 2003;8 Suppl:S36-40. <https://doi.org/10.1046/j.1440-1843.2003.00522.x>
- Undurraga EA, Chowell G, Mizumoto K. COVID-19 case fatality risk by age and gender in a high testing setting in Latin America: Chile, March-August 2020. *Infect Dis Poverty* 2021 Dec;10(1):1-1. <https://doi.org/10.1186/s40249-020-00785-1>
- Munayco C, Chowell G, Tariq A, Undurraga EA, Mizumoto K. Risk of death by age and gender from COVID-19 in Peru, March-May, 2020. *Aging* 2020 Jul 31;12(14):13869-81. <https://doi.org/10.18632/aging.103687>
- Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Int Med* 2020 Jul 1;180(7):934-43. <https://doi.org/10.1001/jamainternmed.2020.0994>
- Sarfaraz S, Shaikh Q, Saleem SG, Rahim A, Herekar FF, Junejo S, et al. Determinants of in-hospital mortality in COVID-19: a prospective cohort study from Pakistan. *PLoS One* 2021 May27;16(5):e0251754. <https://doi.org/10.1371/journal.pone.0251754>
- Raosoft® sample size calculator [internet]. Seattle, WA, USA: Raosoft Inc.; 2004. [accessed 2021 April 10]. Available at: <http://www.raosoft.com/samplesize.html>
- Statistics Kingdom. Proportion confidence interval calculator [internet]. Statistics Kingdom; Melbourne, Australia 2007 [accessed 2021 Apr 10]. Available at: <https://www.statskingdom.com/proportion-confidence-interval-calculator.html>
- Zar JH. *Biostatistical Analysis*. 5th ed. New York: Prentice-Hall, Inc.
- Daniel WW. *Biostatistics: A Foundation for Analysis in the Health Sciences*. 7th ed. Singapore: John Wiley; 2005.

18. Statulator. Statistical Tests [accessed 2021 Apr 10]. Available at: <https://statulator.com/stat/chisq-gof.html>
19. Ain N, Khan S, Marwat M, Khan N, Ahmad I, Ramzan F, et al. Frequency, distribution and determinants of hypertension in adult stroke population of D.I.Khan Division, Pakistan. Gomal J Med Sci 2019 Jul-Sep; 17 (3):81-9. <https://doi.org/10.46903/gjms/17.03.2076>
20. Marwat M, Ahmad I, Ashiq F, AliS, ZamirS, Rehman MU, et al. Frequency, distribution and determinants of diabetes mellitus in adult acute coronary syndrome population of D.I.Khan Division, Pakistan. Gomal J Med Sci 2019 Oct-Dec;17(4):131-43. <https://doi.org/10.46903/gjms/17.04.2106>
21. Naqvi SWA, Saeed S, Rafique A, Saeed MH, Khan N, Khan A, et al. Prevalence and distribution of malaria by sex, age groups and species in year 2019 in suspected malarial population of district D.I.Khan, Pakistan. Gomal J Med Sci 2020 Oct-Dec; 18(4):164-73.
22. Rashid M, Rehman Y, Usman M, Younas M, Bilal M, Jamil M, et al. Distribution of cutaneous leishmaniasis by sex, age groups and residence in year 2020 in cutaneous leishmaniasis population of District D.I.Khan, Pakistan. Gomal J Med Sci 2021 Jan-Mar; 19(1):28-34.

**CONFLICT OF INTEREST**

Authors declare no conflict of interest.  
**GRANT SUPPORT AND FINANCIAL DISCLOSURE**  
None declared.

**AUTHORS' CONTRIBUTION**

The following authors have made substantial contributions to the manuscript as under:

Conception or Design: MA, WA, AK  
Acquisition, Analysis or Interpretation of Data: MA, WA, BA, AK, MF, MA  
Manuscript Writing & Approval: MA, WA, BA, AK, MF, MA

All the authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.



Copyright © 2021. Muhammad Aamir, et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted use, distribution & reproduction in any medium provided that original work is cited properly.